24 Jun 2016 09:49
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
EVG.L Share News (EVG)
EVG Share
Price
EVG Share
News
EVG Share
Chat
EVG Share
Trades
EVG
Live RNS
EVG Share
Charts
EVG Broker
Ratings
EVG Directors
Deals
EVG Financial
Diary
EVG
Fundamentals
EVG Short
Positions
EVG
Media
EVG.L Information
- There is currently no data for EVG
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Evgen Pharma signs service agreement with drug development corsortium
Mon, 13th Feb 2017 08:21
(ShareCast News) - AIM-listed Evgen Pharma has signed a services agreement with a consortium of Cheshire-based drug developments firms for its sulforaphane product.APT Trans, the consortium of drug developers based in the Biohub at Alderley Park, which comprises of Aptus Clinical, Apconix and Seda Pharmaceutical Development Services, aims to help clients transform promising molecules into valued medicines.The deal will support the development of Evgen's lead product SFX-01, a patented composition of synthetic sulforaphane and alpha-cyclodextrin.Ned Wakeman, director of Biohub, said: "The APTrans initiative is a tangible example of how the environment here can accelerate business value. The companies within APTrans all spun out from AstraZeneca, participated in business acceleration programmes, and are thriving in their own right. We are passionate about nurturing an open and collaborative environment where like-minded companies can work, socialise and support each other, and are proud to share in the combined successes of these great companies."Dr Stephen Franklin, founder and chief executive of Evgen Pharma, added: "We selected this excellent group of providers as our partners as they have a proven track record of working well together and they are all co-located at the Biohub where we too have a presence."Shares in Evgen Pharma were up 2.7% to 19p at 0804 GMT.
More News
19 Jan 2016 14:59
Berkeley Group non-exec picks up first shares
(ShareCast News) - First Derivatives non-executive director David Anderson offloaded 5,000 shares in the software and consulting firm at 1,541p each. The sale brought his interest in the company down to 120,000 shares, or 0.5% of the issued share capital. Elsewhere, Berkeley Group non-executive dir
Read more4 Jan 2016 11:52
Evgen appoints new Chief Medical Officer
(ShareCast News) - Evgen Pharma announced the appointment of a new Chief Medical Officer on Monday. The AIM-listed clinical stage drug development company, focused on the treatment of cancer and neurological conditions, said Dr Hamina Patel would be appointed to the post. Dr Patel was described by
Read more9 Sep 2011 16:55
London close: Stocks dive on euro worries
The volatility continued heading into the weekend and stocks were nursing hefty losses at the close of play. The resignation of European Central Bank official Juergen Stark brought the Eurozone crisis into focus. Stark, a German, like many of his compatriots is unhappy about the Bank's policy of b
Read more9 Sep 2011 12:33
Broker tips: Home Retail, Premier Farnell, Evolution
Singer Capital Markets has slashed its target price for FTSE 250 retailer Home Retail Group by 29%, after the group's first half results showed continued tough trading at Argos and a challenging second quarter for Homebase. "Whilst not as bad as feared the continued weakness of trade at Argos and o
Read more9 Sep 2011 12:11
Broker snap: Peel Hunt ups target for Evolution after Investec offer
Following Investec's recommended offer for Evolution, Peel Hunt has raised its target price on the investment banking and stockbroking firm from 86p to 100p to reflect the offer price. Investec, the FTSE 100 South African banking titan, announced on Friday morning that it has made a recommended off
Read more